Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug

Dow Jones

04/25

By Kelly Cloonan

Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer.

The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year.

The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer.

The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 24, 2026 18:18 ET (22:18 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2630087873"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630087873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630087873?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-25 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630087873","market":"us","top_or_hot":-1,"title":"Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. \n</p>\n<p>\n  The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year. \n</p>\n<p>\n  The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer. \n</p>\n<p>\n  The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2026 18:18 ET (22:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-25 06:18</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. \n</p>\n<p>\n  The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year. \n</p>\n<p>\n  The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer. \n</p>\n<p>\n  The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2026 18:18 ET (22:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2630087873","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630087873","pubTimestamp":1777069080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer.The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year.The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer.The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPX":"Compass Therapeutics, Inc."},"translate_title":"Compass Therapeutics股价在胆道癌药物试验数据公布前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. \n\n\n  The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year. \n\n\n  The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer. \n\n\n  The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2026 18:18 ET (22:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}